Consensus on the Management of Liver Injury Associated with Targeted Drugs and Immune Checkpoint Inhibitors for Hepatocellular Carcinoma (Version 2024).

This publication presents a consensus developed by the Chinese Society of Hepatology on managing liver injury induced by...

Continue ReadingConsensus on the Management of Liver Injury Associated with Targeted Drugs and Immune Checkpoint Inhibitors for Hepatocellular Carcinoma (Version 2024).

Stereotactic body radiotherapy versus laparoscopic liver resection for single hepatocellular carcinoma ≤ 5 cm: a retrospective, multicenter, cohort study.

This retrospective study compared stereotactic body radiotherapy (SBRT) and laparoscopic liver resection (LLR) in 383 pa...

Continue ReadingStereotactic body radiotherapy versus laparoscopic liver resection for single hepatocellular carcinoma ≤ 5 cm: a retrospective, multicenter, cohort study.

Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial.

This phase 2 trial assessed the combination of transarterial chemoembolization (TACE) with atezolizumab and bevacizumab...

Continue ReadingTransarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial.